Takeda's stem cell ther­a­py flunks PhI­II test study­ing the drug in Crohn's dis­ease

Take­da’s al­lo­gene­ic stem cell ther­a­py flunked a Phase III study for the treat­ment of a com­mon com­pli­ca­tion of Crohn’s dis­ease, ac­cord­ing to topline da­ta af­ter 24 weeks.

Take­da did not re­lease de­tailed da­ta from the tri­al of dar­vad­stro­cel, mar­ket­ed as Alofisel, on Tues­day, but said that it was “con­tin­u­ing to as­sess the fi­nan­cial im­pacts of the study re­sults, in­clud­ing im­pair­ment loss for in­tan­gi­ble as­sets” for the quar­ter that end­ed Sept. 30.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER